Nyrada Inc
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more
Nyrada Inc (NYR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.453x
Based on the latest financial reports, Nyrada Inc (NYR) has a cash flow conversion efficiency ratio of -0.453x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-4.46 Million) by net assets (AU$9.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nyrada Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Nyrada Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nyrada Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nyrada Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vente Unique.com
PA:ALVU
|
0.416x |
|
Caladrius Biosciences Inc.
LSE:0HS8
|
-0.036x |
|
Kafein Yazilim
IS:KFEIN
|
0.024x |
|
Tetratherix Ltd
AU:TTX
|
-0.098x |
|
BANGO PLC LS-20
F:B1O
|
N/A |
|
BIOMED-LUBLIN WYT.SUR.
F:6NQ
|
N/A |
|
Jetpak Top Holding AB
ST:JETPAK
|
0.027x |
|
Optomed PLC
HE:OPTOMED
|
-0.052x |
Annual Cash Flow Conversion Efficiency for Nyrada Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nyrada Inc from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$3.58 Million | AU$-5.05 Million | -1.412x | -831.05% |
| 2024-06-30 | AU$5.05 Million | AU$-766.29K | -0.152x | +91.07% |
| 2023-06-30 | AU$4.26 Million | AU$-7.23 Million | -1.698x | -565.58% |
| 2022-06-30 | AU$11.50 Million | AU$-2.93 Million | -0.255x | -33.34% |
| 2021-06-30 | AU$14.49 Million | AU$-2.77 Million | -0.191x | +76.02% |
| 2020-06-30 | AU$5.53 Million | AU$-4.41 Million | -0.798x | -297.19% |
| 2019-06-30 | AU$-4.95 Million | AU$-2.01 Million | 0.405x | -20.09% |
| 2018-06-30 | AU$-1.36 Million | AU$-690.18K | 0.506x | -- |